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you out!
Guido Serini & Luca Tamagnone
Secreted class 3 semaphorins (Sema3),
which signal through plexin receptors and
mostly use neuropilins (Nrps) as co-recep-
tors, were initially identified for their abil-
ity to steer navigating axons in the
developing embryo. They were later found
to control angiogenesis in physiological
and pathological settings as well (Serini
et al, 2013). Indeed, the development of a
novel and aberrant vasculature is central
to the pathogenesis of several human
diseases, including cancer and vascular
retinopathies (Goel et al, 2011). A large
body of evidence demonstrates that in
cancer, a massive regression of angiogene-
sis may trigger hypoxia-driven genetic
programs, which in turn can overcome
drug inhibitory mechanisms and ulti-
mately favour cancer cell invasion and
dissemination. Thus, an emerging concept
in molecular medicine is to devise thera-
peutic strategies that, rather than simply
inhibiting angiogenesis, can foster the re-
establishment of a structural and func-
tional normal network, a phenomenon
often referred to as “vessel normalization”
(Goel et al, 2011) (Fig 1). Of note, and in
this context, Sema3A (Maione et al, 2009)
and Sema3F (Wong et al, 2012) have been
reported to favour the normalization of
cancer vasculature and impair metastatic
dissemination.
See also: W-J Yang et al
A lthough Sema3C shares many molec-ular features with the other Sema3family members, unlike other
secreted semaphorins that are mainly found
to act as inhibitors or repulsive factors,
Sema3C appears to have an attracting role in
axon guidance (Sanyas et al, 2012) and
promotes cell migration during embryo
development (Epstein et al, 2015). Both
members of the Nrp family, Nrp1 and Nrp2,
can bind Sema3C, but their functional role
in the signalling cascade is unclear. Notably,
Sema3C has never been found to bind plex-
ins directly; however, both PlexinA2 and
PlexinD1 have been implicated in Sema3C
signalling, based on genetic evidence in
developmental models (Epstein et al, 2015).
The work of Yang and collaborators
published in this issue of EMBO Molecular
Medicine provides the first description of the
molecular mechanisms by which Sema3C
can impact on pathological blood vessel
formation, clearly indicating an inhibitory
activity in this context (Yang et al, 2015).
Moreover, this study proposes potential
therapeutic applications of Sema3C in coun-
teracting pathological angiogenesis by
targeting immature vessel sprouts without
affecting quiescent established vascular
networks (Fig 1). These data are consistent
with another recent study analysing the role
of Sema3C in lymphatic endothelial cells
(LECs) and the vascular network in tumour
progression (Mumblat et al, 2015).
Yang and colleagues employed a mouse
model of oxygen-induced retinopathy (OIR)
that recapitulates the disease observed in
prematurely born babies, whereby localized
hypoxia drives the formation of intravitreal
neovascular tufts. Of note, secreted sema-
phorins (including Sema3A and Sema3C)
are present in the retina during this process,
but their inhibitory activity cannot prevent
new vessel sprouting into the vitreous,
potentially leading to blindness. The authors
found that intravitreal administration of
recombinant Sema3C significantly inhibited
pathologic angiogenesis in the OIR model.
This is in accord with the previous findings
on Sema3A, suggesting that these two mole-
cules, while often displaying divergent func-
tions in development, behave similarly in
angiogenesis.
Sema3C, secreted by both neural crest
cells and the derived smooth muscle cells
(SMCs), was also recently shown to regulate
vascular ECs in a paracrine fashion to
control heart outflow tract septation (Plein
et al, 2015). Consistently, the model elabo-
rated by Yang and colleagues implies that
Sema3C, released by SMCs and pericytes,
acts locally on adjacent ECs to counteract
and balance VEGF-induced angiogenesis.
This inhibitory mechanism seems to be
specific for immature vessels, possibly
because of the selective expression of the
implicated receptors, or simply due to higher
susceptibility to plexin-dependent signals
inhibiting cell-substrate adhesion and
cytoskeletal dynamics. The latter would
imply a constraint mechanism on vessel
sprouting, which would be allegedly over-
come in the presence of strong pro-
angiogenic signals. In their study, Yang and
co-workers demonstrated that a high dose of
Sema3C in the microenvironment could
bolster this restraint, resulting in selective
pruning of immature vessels (Yang et al,
2015). This mechanism may not be merely
based on quantitative balancing of pro-
angiogenic and anti-angiogenic signals, but
could imply a vessel-type-specific combina-
tion of Sema3C receptor components. For
instance, Yang et al (2015) show that
Sema3C inhibitory activity on ECs depends
on the expression of Nrp1 and PlexinD1
that, being enriched in immature new vessel
sprouts, make them especially sensitive to
Sema3C-dependent inhibition. In principle,
Sema3C (or specific PlexinD1 ligands, such
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as Sema3E; Casazza et al, 2012) could
therefore be used to target neo-angiogenic
processes without affecting the normal
vasculature. Notably, according to Mumblat
et al (2015), Sema3C inhibitory activity on
LECs depends on both PlexinD1 and
PlexinA1. Moreover, exogenous Sema3A,
which is thought to signal in ECs via Nrp1
and PlexinA1/A4, was also found to trigger
the apoptosis of aberrant and immature
blood vessels in cancer (Maione et al,
2009); intriguingly, the data suggested that
Sema3A might promote vessel normaliza-
tion also by recruiting SMCs (Fig 1), a
mechanism that was not observed by Yang
et al (2015) for Sema3C. It is conceivable
that, depending on the EC receptor expres-
sion repertoire, different semaphorins may
prove therapeutically viable tools to selec-
tively prune immature and abnormal blood
vessels in specific pathologies, while spar-
ing mature and normal vasculature. In this
respect, further investigation of the specific
expression pattern of semaphorin receptors
in different functional stages of vessels and
ECs would prove highly valuable.
Yang and co-workers found significant
induction of blood vessel EC apoptosis by
Sema3C, while Mumblat et al (2015)
observed reduced LEC proliferation; VEGF
signalling was partly impaired, but the
implicated mechanisms were not elucidated.
In both studies, Sema3C treatment elicited
rapid actin cytoskeleton remodelling and
loss of cell-substrate adhesion; moreover,
Yang et al (2015) report that, in response to
Sema3C, ECs undergo fast remodelling of
cell–cell junctions as well. The observed
phenotype recalls the typical cellular
“collapse” or contraction, well described in
response to other semaphorins (Barberis
et al, 2004). It can be postulated that ECs
that are unable to efficiently adhere to the
extracellular matrix or form stabilizing cell
junctions, especially if they lack support
from mural cells in immature vessels, are
then primed to enter apoptosis. Notably, the
Tufro laboratory had reported instead that
Sema3C promotes glomerular EC adhesion,
migration, and proliferation (Banu et al,
2006). The possibility remains therefore that
ECs from different vascular beds might
display divergent biological responses to
Sema3C, possibly due to the different
expression profile of cell surface receptors.
Another mechanistic aspect investigated
by Yang et al (2015) is the regulatory role
of proteolytic cleavage in Sema3C signalling
(Fig 2). Similar to other secreted semaphorins,
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Figure 2. Sema3C activity is regulated by proteolytic cleavage.
Sema3C is synthesized as a secreted full-length molecule, with a basic-charged C’-tail putatively tethering it to the cell surface and interacting with the co-receptor Nrp1.
MMPs have been found to remove this C’-sequence, enhancing Sema3C extracellular diffusion. On the other hand, furin-like convertases are found to release the sema domain
from the rest of the molecule; this ablates the inhibitory activity for EC and vessels, but allegedly preserves other functions, such as tumour promotion.
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Figure 1. Sema3 proteins display vascular normalizing properties.
Secreted Sema3A (Maione et al, 2009), Sema3C (Yang et al, 2015), and Sema3F (Wong et al, 2012) promote the
functional normalization of pathological blood vessels that are devoid of pericyte ensheathment. Of note, both
Sema3A (Maione et al, 2009) and Sema3C (Yang et al, 2015) appear to selectively elicit the apoptosis EC
belonging to immature, but not mature blood vessels (upper panel). In addition, Sema3A has chemoattractive
activity towards cultured SMCs (Maione et al, 2009), supporting the hypothesis that at least this Sema3may also
favour the recruitment of pericytes on immature blood vessels (lower panel).
EMBO Molecular Medicine ª 2015 The Authors
EMBO Molecular Medicine Sema3C is a novel vascular normalizing factor Guido Serini & Luca Tamagnone
2
Published online: August 26, 2015 
Sema3C is the target of furin family proteases,
which can detach the sema and PSI domains
from the C-terminal portion known to bind
Nrp1, which is a key component of the
receptor complex. Indeed, furin cleavage was
found to blunt inhibitory signals mediated by
all semaphorins that depend on Nrps, includ-
ing Sema3C (as confirmed in this study). By
analogy to Sema3A and Sema3B, this
increases the interest in engineering furin-
resistant Sema3C variants with increased
functional stability, for therapeutic applica-
tions. Of note, one could envision that the
immature-vessel-specific activity of the cleav-
able Sema3C used in this study may be
influenced by its capacity to elicit a strong,
but short-lived inhibitory signalling in ECs.
Sema3C is also the target of metallopro-
teases (MMPs), which only release a very
short C-terminal sequence (Esselens et al,
2010); while not significantly affecting
protein structure, this event removes the
main Nrp1-binding sequence. According
to Yang and co-workers, unlike furin-
processed Sema3C, MMP-processed Sema3C
is functionally competent for EC inhibition,
which leaves open the question on the
requirement for Nrp1 signalling in this
pathway, and would suggest a currently
unknown function of the Ig-like domain
of Sema3C (Fig 2). Esselens and co-
workers had shown that MMP-processed
Sema3C promotes tumour cell migration
(Esselens et al, 2010); furthermore, Lee and
Yutzey (2011) showed that Sema3C expres-
sion is induced by Twist1, an epithelial to
mesenchymal transition (EMT)-inducing
transcription factor implicated in cancer
progression. Finally, Mumblat et al (2015)
showed that furin-cleaved Sema3C, while
deficient for inhibitory activity on ECs, can
promote cancer cell viability. These find-
ings fit with the multiple reports indicating
elevated expression of Sema3C in highly
malignant human tumours and suggest the
ability of tumour cells to switch Sema3C
function from an anti-angiogenic to a
growth-promoting one, by means of prote-
olytic processing. There is as yet little
evidence suggesting an important role of
proteolytic processing in attractive Sema3C
functions in neural and cardiac develop-
ment. Thus, the current scenario nominates
Sema3C as a dual-function molecule, simi-
lar to Sema3E (which intriguingly also
relies on PlexinD1 as major signalling
receptor). Further studies will allow the
elucidation of the different signalling
cascades responsible for these apparently
divergent functional activities of Sema3C.
In conclusion, while Sema3C has so far
been mainly considered as an attractive cue
for neurons and a promoter of developmen-
tal morphogenesis, the study of Yang and
co-workers reveals how, in mouse models,
recombinant Sema3C may effectively and
selectively block hypoxia-driven aberrant
angiogenesis, without affecting normal
quiescent vessels. The data also suggest that
differential expression of receptors in target
cells and proteolytic maturation of Sema3C
may switch between these apparently antag-
onistic functions. Further insights into these
aspects will allow full understanding of the
activity of this semaphorin, with an eye to
its application in medicine for blocking
pathological angiogenesis, such as in retino-
pathies and cancer.
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